Form 4: Director Peter J. Arduini Acquires BMY Deferred Shares

Bristol-Myers Squibb director Peter J. Arduini acquired 577.082 deferred share units as part of director compensation.

Summary

• Director Peter J. Arduini acquired 577.082 Deferred Share Units (DSUs) on March 31, 2026.
• The acquisition price was $60.65 per unit.
• Following this transaction, the director holds a total of 71,435.166 shares beneficially owned.
• These units are part of the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Demonstrates continued alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Value of deferred share units is subject to the market performance of Bristol-Myers Squibb common stock.

Future Outlook

The deferred share units will be converted into common stock upon the reporting person ceasing to be a director or at a previously specified future date.

Industry Context

StockSavvy.ai notes that director equity acquisitions via deferred compensation plans are standard corporate governance practices in the pharmaceutical industry, intended to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of deferred share units for non-employee directors is consistent with compensation structures at peer companies like Pfizer, Merck, and Eli Lilly.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Conversion of deferred share units to common stock upon the director's departure or specified future date.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Insider Trading, Form 4, Director Compensation, Deferred Share Units